Antibody-guided drug shows encouraging activity in metastatic breast cancer.
D000906:Antibodies / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001943:Breast Neoplasms / Q000276:immunology* / Q000628:therapy*; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D009362:Neoplasm Metastasis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D015398:Signal Transduction; D013997:Time Factors; D000068878:Trastuzumab; D016896:Treatment Outcome
D000906:Antibodies; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human